ACHILLION PHARMACEUTICALS INC Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016	FY2015 12 months to Dec 31, 2015	FY2014 12 months to Dec 31, 2014
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
Noncash stock-based compensation
Loss on disposal of equipment
Premium on purchases of marketable securities
Amortization of (discount) premium on marketable securities
Changes in operating assets and liabilities:
Accounts and other receivables
Prepaid expenses and other current assets
Accounts payable
Accrued expenses
Other long-term liabilities
Net cash used in operating activities
Cash flows from investing activities
Purchase of fixed assets
Purchase of marketable securities
Maturities of marketable securities
Proceeds from issuance of common stock, net of issuance costs
Public Offering
Stock Purchase Agreement
Total proceeds from issuance of common stock, net of issuance costs
Net cash provided by investing activities

Cash flows from financing activities
Proceeds from exercise of stock options
Proceeds from exercise of warrants
Proceeds from sale of stock under the employee stock purchase plan
Payment of deferred financing costs
Borrowings of debt
Repayments of debt
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents, beginning of period
Cash and cash equivalents, end of period
Net cash provided by (used in) financing activities

Net increase (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash, beginning of period
Cash, cash equivalents and restricted cash, end of period
Supplemental disclosure of cash flow information
Cash paid for interest
Supplemental disclosure of noncash investing and financing activities
Cashless exercise of warrants
Purchases of equipment in accounts payable or accrued expenses

Comments